Related references
Note: Only part of the references are listed.Safety of rasagiline for the treatment of Parkinson's disease
Santiago Perez-Lloret et al.
EXPERT OPINION ON DRUG SAFETY (2011)
Clinical Pharmacology Tyramine Challenge Study to Determine the Selectivity of the Monoamine Oxidase Type B (MAO-B) Inhibitor Rasagiline
Tamar Goren et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Clinical neuroprotection in Parkinson's disease - Still waiting for the breakthrough
Matthias Loehe et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2010)
Long-term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
ARCHIVES OF NEUROLOGY (2009)
Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2009)
Adherence to Antiparkinson Medication in a Multicenter European Study
Donald Grosset et al.
MOVEMENT DISORDERS (2009)
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
C. Warren Olanow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease
Fabrizio Stocchi
PARKINSONISM & RELATED DISORDERS (2009)
Orally disintegrating selegiline for the treatment of Parkinson's disease
Matthias Löhle et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Epidemiology of Parkinson's disease
Guido Alves et al.
JOURNAL OF NEUROLOGY (2008)
Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?
Carl E. Clarke
MOVEMENT DISORDERS (2008)
A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis
D. Grosset et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2007)
Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease
Jack J. Chen et al.
CLINICAL THERAPEUTICS (2007)
Minimal clinically important change on the Unified Parkinson's Disease Rating Scale
Anette Schrag et al.
MOVEMENT DISORDERS (2006)
Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl]
S Yasar et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Timing of treatment initiation in Parkinson's disease: A need for reappraisal?
AHV Schapira et al.
ANNALS OF NEUROLOGY (2006)
Suboptimal medication adherence in Parkinson's disease
KA Grosset et al.
MOVEMENT DISORDERS (2005)
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
O Rascol et al.
LANCET (2005)
Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years
MA Hely et al.
MOVEMENT DISORDERS (2005)
The role of radiotracer imaging in Parkinson disease
B Ravina et al.
NEUROLOGY (2005)
Drug adherence in Parkinson's disease
NA Leopold et al.
MOVEMENT DISORDERS (2004)
Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients
NJ Ives et al.
BMJ-BRITISH MEDICAL JOURNAL (2004)
Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease
F Blandini et al.
EXPERIMENTAL NEUROLOGY (2004)
The scientific basis for the current treatment of Parkinson's disease
CW Olanow
ANNUAL REVIEW OF MEDICINE (2004)
A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition
A Clarke et al.
JOURNAL OF NEURAL TRANSMISSION (2003)
Swallowing disorders in Parkinson's disease
A Potulska et al.
PARKINSONISM & RELATED DISORDERS (2003)
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
AL Whone et al.
ANNALS OF NEUROLOGY (2003)
Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study
T Caraceni et al.
PARKINSONISM & RELATED DISORDERS (2001)
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline
A Kupsch et al.
JOURNAL OF NEURAL TRANSMISSION (2001)
The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture
J Goggi et al.
NEUROREPORT (2000)
A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
O Rascol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
